Clene Inc (CLNNW) - Total Assets
Based on the latest financial reports, Clene Inc (CLNNW) holds total assets worth $22.31 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CLNNW book value for net asset value and shareholders' equity analysis.
Clene Inc - Total Assets Trend (2017–2024)
This chart illustrates how Clene Inc's total assets have evolved over time, based on quarterly financial data.
Clene Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Clene Inc's total assets of $22.31 Million consist of 59.1% current assets and 40.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.5% |
| Accounts Receivable | $391.00K | 1.4% |
| Inventory | $68.00K | 0.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Clene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CLNNW market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clene Inc's current assets represent 59.1% of total assets in 2024, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 44.5% of total assets in 2024, up from 0.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 1.4% of total assets.
Clene Inc Competitors by Total Assets
Key competitors of Clene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Clene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.53 | 0.83 | 5.40 |
| Quick Ratio | 1.52 | 0.82 | 5.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.37 Million | $-4.13 Million | $51.32 Million |
Clene Inc - Advanced Valuation Insights
This section examines the relationship between Clene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -47.8% |
| Total Assets | $27.34 Million |
| Market Capitalization | $17.62 USD |
Valuation Analysis
Below Book Valuation: The market values Clene Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Clene Inc's assets decreased by 47.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Clene Inc (2017–2024)
The table below shows the annual total assets of Clene Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $27.34 Million | -47.77% |
| 2023-12-31 | $52.34 Million | +17.64% |
| 2022-12-31 | $44.49 Million | -29.45% |
| 2021-12-31 | $63.06 Million | -7.59% |
| 2020-12-31 | $68.24 Million | +358.71% |
| 2019-12-31 | $14.88 Million | -68.45% |
| 2018-12-31 | $47.16 Million | +49543.15% |
| 2017-12-31 | $95.00K | -- |
About Clene Inc
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis … Read more